Navigation Links
Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
Date:8/27/2013

at, Syndax's lead product candidate, has been studied in more than 800 cancer patients where objective tumor responses have been observed in both solid and hematologic malignancies. Entinostat's established safety and efficacy profile as both a single agent and in combination with a number of commercially available targeted therapies differentiates it from other histone deacetylase inhibitors (HDACi). Having demonstrated promising clinical results in breast and lung cancer, entinostat is moving toward pivotal clinical testing. It is an oral, novel inhibitor of class I histone deacetylases, key enzymes that alter the structure of chromatin to control gene expression. This aberrant gene expression can result in reversible, epigenetically-based drug tolerance. Designed to selectively target the HDAC isoforms most relevant to the biology of tumors, entinostat can normalize dysregulated gene expression in cancer cells, thereby restoring sensitivity to targeted therapy. Entinostat is the first HDACi with positive results in a randomized Phase 2 study in breast cancer and is the only HDACi in late-stage development for this indication.

About Syndax Pharmaceuticals

Syndax is focused on employing epigenetic strategies to overcome the problem of resistance in oncology care in solid tumors. The company holds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor in late-stage clinical development for the treatment of advanced breast cancer and lung cancer. A randomized, placebo-controlled Phase 2 study of entinostat in combination with aromatase inhibitors in breast cancer (ENCORE 301) demonstrated an improvement in both progression-free survival and overall survival, providing the basis for the evaluation of entinostat in pivotal Phase 3 testing in metastatic breast cancer.  Entinostat also demonstrated promising results in a subset of non-small cell lung cancer patients when given in combination with the EGFR-TKI
'/>"/>

SOURCE Syndax Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Syndax Pharmaceuticals to Present Updated Overall Survival Data With Entinostat in Metastatic Breast Cancer at ASCO
2. Syndax Pharmaceuticals Announces Publication of Clinical Study Demonstrating that Entinostat Targets Resistance Pathways in Breast Cancer
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
6. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
7. Icahn Issues Statement Regarding Amylin Pharmaceuticals
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
11. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... LOS ANGELES , Sept. 30, 2014   ... apnea shopping destination , today announced that it now ... ResMed . AirSense CPAPs are the first sleep apnea ... makes it simple and easy to track and share ... the overall effectiveness of their CPAP therapy.  In addition, ...
(Date:9/30/2014)... BRUNSWICK, N.J., Sept. 30, 2014 The ... Kessler Foundation and New Jersey Health Foundation (NJHF) ... and patient care programs has been announced by ... officer of Kessler Foundation and James M. ... "The experience of New Jersey Health ...
(Date:9/30/2014)... -- The Eastern European medical device industry is in ... as new medical-device manufacturers are constantly trying to penetrate ... to reduce the cost incurred for placing their products ... effective means to achieve this target. This research service ... and provides profiles of key distributors in ...
Breaking Medicine Technology:Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4Kessler Foundation Partners with New Jersey Health Foundation To Start Innovative Companies To Change the Lives of People with Disabilities 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3
... DIEGO, Aug. 28 Vical Incorporated,(Nasdaq: VICL ... subject in its,Phase 1 trial of the company,s ... placebo-controlled trial will,evaluate safety, tolerability and immune responses ... 45 at two U.S. clinical sites. "We ...
... such ... infectious-disease outbreaks, SEATTLE, Aug. 28 In ... Fred,Hutchinson Cancer Research Center confirm that the avian influenza A ... within a family in,Indonesia. The findings, by biostatistician Ira M. ...
Cached Medicine Technology:Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza 2Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza 3Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza 4Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006 2Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006 3Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006 4
(Date:9/30/2014)... Las Vegas, NV (PRWEB) September 30, 2014 ... Marshall as a free introduction to SurvivalLife.com along with a ... has caught the attention of Shane Michaels, prompting an investigative ... the most well-known people in the survival and preparation niche, ... with all of the great classes and survival products that ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... is helping people perform better in and out of the ... and memory has caught the attention of Shane Michaels, prompting ... day-to-day grind, fatigue is the reason most people simply just ... whether that means staying focused at work, getting the motivation ...
(Date:9/30/2014)... 30, 2014 VisitandCare.com reports ... has gone up more than 79 percent in 2014, ... company also reported total revenue tripled for its entirety ... company’s professional strategy has allowed them to partner with ... for patient comfort and privacy — with state-of-the-art surgical ...
(Date:9/30/2014)... September 30, 2014 Hospice & ... annual “In Celebration” gala, honoring three outstanding individuals ... of striving to provide extraordinary and dignified comfort, ... a serious or life-limiting illness. , The event ... Rye, NY and recognized William (Bill) J. McGuinness, ...
(Date:9/30/2014)... Regenerative Medicine Solutions (RMS) is set to open ... RMS welcomes the launch of an entirely new facility, ... new treatment center for the Lung Institute. , ... Nashville, the hope is to bring awareness to those ... undiagnosed. With Nashville being a hub for medical technology, ...
Breaking Medicine News(10 mins):Health News:EverStryke: Review Exposes Joe Marshall’s Permanent Match Survival Product 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 2Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 3Health News:VisitandCare.com Announces Record Demand for Plastic Surgery in Turkey 4Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Regenerative Medicine Solutions Expanding 2
... have covered one-third of the country's children in a ... than 11 million children in 1,301 counties of central ... hepatitis B, said Jiang Zuojun, the Vice-Minister for Health. ... their pace to reach the remaining two-thirds by the ...
... incidence of breast cancer at Brisbane's ABC headquarters at Toowong ... ,ABC managing director Mark Scott said that Dr Joanne Aitken ... by Dr Bruce Armstrong. ,Mr Scott added that ... alongside the panel. ,The review panel was established ...
... The British government's drug watchdog has warned yesterday that the doctors ... bipolar disorder in spite of it being one of the most ... are waiting on an average for eight years to be accurately ... almost 20 years of ill health, of which they might not ...
... poll that was conducted by the nursing union of the ... and harassment a continuing problem in// healthcare. ,Stating ... have suffered abuse from fellow staff and managers over the ... those bullied had wanted changes in their work so as ...
... Industry (ABPI) and the BioIndustry Association (BIA) recommended new ... with extreme care and caution while testing pioneering drugs. ... March left six volunteers in the state of coma. ... The new drug was tested at the Parexel trial ...
... studies shows that alternative and complementary therapies may have ... menopause.// The review article is published in the July ... the JAMA/Archives journals. ,Twenty-five million women will ... of them will experience hot flashes, night sweats, vaginal ...
Cached Medicine News:Health News:Breast Cancer Review Panel Adds Two Experts 2Health News:Bipolar Disorder Not Being Accurately Diagnosed By Doctors In UK 2Health News:Alternative Therapies May Not Ease Menopause Symptoms 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: